Columbia Laboratories, Inc. (NASDAQ:CBRX) announced the launch of a new website (crinoneusa) to educate women about the role of progesterone in fertility and pregnancy. This new website provides helpful information on the role of progesterone, the 'pregnancy hormone,' in preparing a woman's body for pregnancy and helping her to maintain a pregnancy. In addition, this website features clinical data on progesterone vaginal gel for healthcare providers.
This new website includes comprehensive information, support and resources on the important role progesterone plays in helping women achieve and maintain a healthy pregnancy. Progesterone is often prescribed for women undergoing infertility treatment, including assisted reproductive technologies (ART), and for women during the first trimester of pregnancy with progesterone deficiency. Infertility affects one in eight couples in the U.S., or 12 percent of women of reproductive age.
"Progesterone plays a vital role in achieving pregnancy and helping to maintain a healthy pregnancy yet, until now, there has been little information available to women on this important 'pregnancy hormone,'" said Robert S. Mills, president and chief executive officer of Columbia Laboratories. "Columbia is dedicated to providing patients with the resources they need to make informed treatment decisions, and offering convenient, effective treatment options to help them achieve their dream of parenthood."
This new website features information on a woman's menstrual cycle, on the role of progesterone in infertility treatment and pregnancy, and other resources for women. There is also a dedicated section for healthcare professionals, which features clinical data on Crinone® 8% (progesterone vaginal gel) in both infertility treatment and pregnancy.
About Progesterone
During pregnancy, progesterone, the pregnancy hormone, helps to maintain the lining of the uterus, providing necessary nutrients to support and nurture a fertilized egg.
Before ovulation, progesterone levels in a woman's body remain relatively low, but rise after ovulation during the latter part of a woman's menstrual cycle, which is called the luteal phase. The luteal phase begins with the production of progesterone and ends with either pregnancy or menstruation, when the uterus sheds its lining. Most women undergoing infertility treatment need progesterone supplementation to help prepare the uterus for implantation and development of a fertilized egg.
About CRINONE® 8%
CRINONE ® 8% is the first FDA-approved and only once-daily natural progesterone gel for progesterone supplementation or replacement as part of ART treatment for infertile women with progesterone deficiency. CRINONE 8% is approved for use in the first trimester of pregnancy and has been used for a decade by tens of thousands of women globally to help sustain pregnancy in the first trimester. Its unique bioadhesive delivery system provides controlled and sustained release of progesterone directly to the uterus, where it is needed. For more information, please visit crinoneusa.
The most common side effects of CRINONE 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE 8% is contraindicated in patients with active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs.
CRINONE® is a registered trademark of Columbia Laboratories, Inc.
About Columbia Laboratories
Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of women's healthcare and endocrinology products that use its novel bioadhesive drug delivery technology. Columbia markets CRINONE® 8% (progesterone gel) in the United States for progesterone supplementation as part of Assisted Reproductive Technology treatment for infertile women with progesterone deficiency.
columbialabs
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the successful marketing of CRINONE® 8% (progesterone gel) in the U.S.; the timely and successful development of new products; the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.
Columbia Laboratories, Inc.
View drug information on Crinone 8%.
Buy Biaxin Without Prescription
Комментариев нет:
Отправить комментарий